Corteva Warns Brazil Deterioration Persists, Inventory Overhang to Hit Q4
CTVA is trading near its 52-week low of $9.14 (7.4% above the low).
Summary
On the Q3 call, management said Brazil conditions deteriorated sharply in the final weeks of the quarter and the negative trend is continuing. Corteva entered 2026 carrying more of its own inventory in the channel than expected, and it is not assuming any meaningful improvement in Brazilian purchasing behavior for the rest of the year. That inventory will weigh on Q4 results, though the company expects levels to normalize by the end of the growing season. Cost actions are already underway: a hiring freeze is in place and certain R&D projects are being shelved for a year. Management is refusing to extend payment terms or offer credit to past-due Brazil distributors, and the CEO expects a return to growth in 2027, with 2H27 outperforming 2H26 if the inventory overhang clears. This follows yesterday's Q3 loss of $54 million, or $0.08 a share, on a 9% sales decline to $1.59 billion and the FY26 EBITDA guidance cut disclosed in today's 8-K.
At the time of this announcement, CTVA was trading at $9.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $9.14 to $14.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.